Paper Details

  1. Home
  2. Paper Details

Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults.

Author: BenoitY, BuryJ, DelbekeM J, FièreD, OttenJ, SolbuG, StryckmansP A, SuciuS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 217 patients with acute lymphoblastic leukemia in complete remission compared two consolidation chemotherapy regimens (P and M) and two maintenance treatments (chemotherapy and immunotherapy). Consolidation P caused more toxicity but showed no significant difference in disease-free interval or survival compared to M. Chemotherapy maintenance showed significantly better disease-free interval than immunotherapy, particularly in patients with lower hemoglobin levels at diagnosis. However, there was no significant difference in survival between the maintenance treatments.
Paper Details　
Original Abstract of the Article :
Two hundred and seventeen patients, 1-50 yr old, with acute lymphoblastic leukemia in complete remission were randomized to receive a 1-yr consolidation chemotherapy of either type P, comprising 7 different drugs, or type M, consisting of methotrexate interspersed with prednisone and vincristine. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/6576814

データ提供：米国国立医学図書館（NLM）

Chemotherapy vs. Immunotherapy for Acute Lymphoblastic Leukemia: A Head-to-Head Comparison

This research compares the effectiveness of chemotherapy and immunotherapy for maintaining remission in patients with acute lymphoblastic leukemia (ALL). The authors conducted a randomized controlled trial involving 217 patients, investigating the impact of different consolidation and maintenance therapies on disease-free interval (DFI) and overall survival. The study revealed that chemotherapy demonstrated superior efficacy in maintaining remission compared to immunotherapy, particularly for patients with lower hemoglobin levels at diagnosis. However, immunotherapy may offer potential benefits in terms of long-term survival after relapse. This research highlights the need for further investigations to optimize treatment strategies for ALL.

Chemotherapy: A More Effective Maintenance Strategy for ALL

The study's findings suggest that chemotherapy is currently a more effective maintenance strategy for ALL compared to immunotherapy. The author notes that chemotherapy demonstrated significantly better DFI, especially for patients with lower hemoglobin levels at diagnosis. However, the author acknowledges that immunotherapy may provide potential benefits in terms of long-term survival after relapse.

The Evolving Landscape of ALL Treatment: A Balancing Act

This research emphasizes the complex and evolving nature of ALL treatment. The author highlights the importance of ongoing research to explore new treatment options and refine existing strategies for achieving optimal outcomes. The study underscores the need for a balanced approach to ALL treatment, carefully weighing the potential benefits and risks of different therapies based on individual patient characteristics and disease stage.

Dr.Camel's Conclusion

The journey to cure ALL is like a camel caravan navigating a treacherous desert landscape. This research, like a guidepost in the desert, compares different paths to achieve remission and survival. It reminds us that the quest for a cure is ongoing, with each new study illuminating the way towards better treatment options for those battling this disease.

Date :
  1. Date Completed 1983-10-08
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

6576814

DOI: Digital Object Identifier

S0006-4971(20)84517-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.